Cogent Biosciences, Inc. (NASDAQ: COGT) reported a net loss of $97.4 million for the first quarter ended March 31 2026, a widening from the $72.0 million loss recorded in the same period last year. The company also posted earnings per share of $‑0.60, missing the consensus estimate of $‑0.53 by $0.07.
Research and development costs climbed to $75.4 million, up from $63.0 million year‑over‑year, reflecting continued investment in clinical development of bezuclastinib and the expansion of the commercial organization. General and administrative expenses rose to $28.2 million from $11.9 million, driven by hiring and infrastructure costs associated with the anticipated launch of bezuclastinib in systemic mastocytosis and gastrointestinal stromal tumor.
The company’s cash balance stood at $866.4 million as of March 31 2026, bolstered by a $45.7 million at‑market equity offering and an $18.0 million milestone payment from Plexxikon. Non‑cash stock‑based compensation totaled $16.9 million, comprising $8.9 million in R&D and $8.0 million in G&A.
"2026 is shaping up to be a pivotal year for Cogent,” said President and CEO Andrew Robbins. “We have two NDAs for bezuclastinib under FDA review and expect to submit a third in the first half of this year. With a strong balance sheet, we are focused on completing our commercial build and preparing for multiple potential launches.”
The results underscore the company’s strategy of investing heavily in pipeline development while maintaining a robust cash runway that extends through 2028. The widening loss is largely attributable to one‑time charges and the accelerated build‑out of the commercial team, positioning Cogent to capitalize on the expected regulatory approvals and market entry of bezuclastinib later in 2026.
Management did not update its quarterly guidance, but reiterated its focus on expediting regulatory review and building the commercial infrastructure needed for a rapid market entry. The company remains confident that its strong cash position and ongoing pipeline progress will support its long‑term growth objectives.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.